# A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

> **NCT07652658** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 359 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **OTHER:** Placebo for AZD8965
- **DRUG:** AZD8965 low dose
- **DRUG:** AZD8965 medium dose
- **DRUG:** AZD8965 high dose

## Key facts

- **NCT ID:** NCT07652658
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-11
- **Primary completion:** 2028-09-14
- **Final completion:** 2028-09-14
- **Target enrollment:** 359 (ESTIMATED)
- **Last updated:** 2026-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652658, "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*